Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2015

View Archived Issues

Pivotal phase III trial of galeterone for metastatic castration-resistant prostate cancer

FDA grants BLZ-100 orphan status for visualizing brain tumors

Celator Pharmaceuticals reports induction response data from phase III study of CPX-351

ESHG highlights: characterization of disease-associated gene mutations

Perle studies combination of oral cyclosporine and lansoprazole for type 1 diabetes

NIAAA initiates trial of Horizant for alcohol use disorder

Novogen advances anisina towards clinic

Scripps Research Institute receives NIH grant for novel diabetes treatments

Radicut approved in Japan for amyotrophic lateral sclerosis

VIB and Vrije Universiteit Brussel spin out Confo Therapeutics

Trial finds RVX-208 may benefit individuals with prediabetes

Zosyn receives approval for the additional indication of febrile neutropenia in Japan

Humira recommended for approval for hidradenitis suppurativa in E.U.

Enrollment begins in global phase Ib study of QR-010 in cystic fibrosis

CHMP adopts positive opinions for Strensiq and Kanuma

Farydak recommended by CHMP to treat multiple myeloma

UCB seeks Japanese approval for lacosamide for partial onset seizures

EMA committee recommends approval of Raxone for Leber's hereditary optic neuropathy

RepliCel describes the potential of cell therapies to treat tendinosis and aging skin

European approval of Simponi for non-radiographic axial spondyloarthritis

Aurigene Discovery Technologies discloses RORgamma modulators

Merck & Co. reports development of gamma-secretase inhibitors

Baylor College of Medicine and Elex Biotech report RyR2/FKBP12.6 complex antagonists

AbbVie develops bromodomain inhibitors

Allergan synthesizes S1P1 ligands

Phase I data influence future development of LY-3022856

Immunomodulatory progenitor cells show promise to mitigate ICR in heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...